Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Thoracic Neoplasms 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1

Interventions

Carboplatin 283Cisplatin 225Pemetrexed 196Paclitaxel 151Docetaxel 132pembrolizumab 109Gemcitabine 94Etoposide 64Erlotinib Hydrochloride 59Radiotherapy 54Vinorelbine 47durvalumab 46Gefitinib 46Bevacizumab 46atezolizumab 42Nivolumab 40Drug Therapy 34osimertinib 30Topotecan 29tislelizumab 23130-nm albumin-bound paclitaxel 23Radiosurgery 21Ipilimumab 18Crizotinib 18Magnetic Resonance Spectroscopy 15Albumin-Bound Paclitaxel 15Surgical Procedures, Operative 14aumolertinib 13Platinum 13Injections 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × TNFSF10 protein, human × Thoracic × Clear all
NCT03083743 2017-03-20

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Shanghai Gebaide Biotechnology Co., Ltd.

Phase 3 Unknown
417 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡